Retatrutide
Retatrutide
Retatrutide is an investigational triple-agonist peptide (GLP-1/GIP/glucagon receptor) showing unprecedented weight loss results in clinical trials — up to 24% body weight reduction.
Pricing Overview
Brand / Retail Price
Not yet available (investigational)
Compounded / Cash Pay
$200–$700/month (research peptide suppliers)
Expected to launch at premium pricing — compare early options on Script Unlock
Primary Uses
How Retatrutide Works
Retatrutide activates three receptors simultaneously: GLP-1 (appetite suppression), GIP (metabolic regulation), and glucagon (energy expenditure/fat burning), creating a synergistic triple-hormone effect.
Dosing Information
Typical Dose
1mg–12mg weekly (clinical trials)
Frequency
Once weekly
Administration
Subcutaneous injection
Notes
Not yet FDA approved — Phase 3 trials ongoing
Side Effects & Safety
Common
- • Nausea
- • Diarrhea
- • Vomiting
- • Decreased appetite
Serious
- • Under investigation — limited long-term safety data
Rare
- • Under investigation
Frequently Asked Questions
When will retatrutide be FDA approved?
Retatrutide is currently in Phase 3 clinical trials by Eli Lilly. FDA approval could come as early as 2026–2027 if trials are successful.
Is retatrutide better than tirzepatide?
Early data suggests retatrutide may produce greater weight loss (24% vs 22.5%) due to its triple-agonist mechanism, but head-to-head trials are needed.
Related Peptides
Compare Retatrutide Prices
Upload your Retatrutide prescription and receive competitive bids from verified compounding pharmacies.
Get Retatrutide Quotes